8 research outputs found
Descriptive overview of the study population at start of follow-up.
Descriptive overview of the study population at start of follow-up.</p
Crude vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance.
(DOCX)</p
Adjusted VE against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance.
(A) Alpha variant (B.1.1.7), 20 February–15 June 2021. (B) Delta variant (B.1.617.2), 4 July–20 November 2021. (C) Omicron variant (B.1.1.529), 21 December 2021–31 January 2022. VE adjusted for age, sex, country of origin, comorbidity, staying at hospital, calendar time, and test incidence. CI, confidence interval; SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus 2; VE, vaccine effectiveness.</p
Adjusted VE against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance.
Adjusted VE against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance.</p